消息發布
United Biomedical, Inc. (UBI) receives Bill and Melinda Gates Foundation Grand Challenges Explorations grant for a new approach to an AIDS vaccine
UBI was encouraged to propose research on a preventative AIDS vaccine aimed at the human immunodeficiency virus (HIV) gp120 CD4 binding site by the availability of 3D molecular models for the infection process and by discoveries of broadly neutralizing antibodies that target gp120. The UBI proposal was supported by the company's long term background in research and development of synthetic peptide HIV vaccines and immunotherapeutics using both anti-virus and anti-cell receptor approaches for prevention and treatment of HIV infection. UBI will begin clinical trials this winter in AIDS patients using a monoclonal anti-cell antibody approach. Another anti-cell immunotherapeutic vaccine approach is also expected to begin clinical trials in patients in the United States in 2010.
"We are honored that our creative and innovative plan to design a new kind of vaccine for AIDS has been recognized by the Bill and Melinda Gates Foundation with the award of a highly competitive Grand Challenges Explorations grant. Based on our long experience in the AIDS vaccine and immunotherapy fields, and our accomplishments with other designer peptide vaccines, we have high expectations for significant success after our 20 year struggle to develop a protective vaccine to stop the worldwide HIV epidemic," said Dr. Chang Yi Wang, the research team leader and company CEO.
"The highly conserved CD4 binding site of gp120 is an attractive vaccine target, since it is used by all variants of HIV in the process of attachment to the host cell. While many prior attempts have failed to yield protective antibodies to this part of the virus, UBI's approach is novel and is backed up by their platform technology which is able to elicit normally disfavored immune responses," said long time collaborator Dr. Carl Hanson, a prominent HIV virologist and research scientist at the California Department of Public Health, Richmond, CA USA.
About United Biomedical, Inc.
UBI is a privately held international bio/pharmaceutical company striving to address unmet global needs for disease prevention and treatment with a set of proprietary technologies based on designer peptides and complimentary vaccine delivery systems which has given UBI a product portfolio of high impact immunotherapeutic and vaccine products. Additional information about UBI is available at https://www.ubi-group.global/.
The information in this press release should be considered accurate only as of the date of the release. UBI has no intention of updating and specifically disclaims any duty to update the information in these press releases. The press release may contain forward-looking statements involving risks and uncertainties and UBI's actual results may differ materially from those in the forward-looking statements.
About the Bill and Melinda Gates Foundation
The Bill & Melinda Gates Foundation, based in Seattle, Washington, is the largest transparently operated private foundation in the world, founded by Bill and Melinda Gates (www.gatesfoundation.org).
About Grand Challenge Exploration
Grand Challenges Explorations (www.gatesfoundation.org/global-health/Pages/grand-challenges-explorations.aspx) is an initiative of the Gates Foundation to promote innovation in global health. Priority Areas of Focus include working on infectious diseases by developing ways to fight and prevent enteric and diarrheal diseases, HIV/AIDS, malaria, tuberculosis, and neglected and other infectious diseases.
Contact:
Ms. Francine Volz
Public Relations
Tel: (631) 273-2828
Fax: (631) 273-1717
Web Page: www.unitedbiomedical.com
fvolz@unitedbiomedical.com